In this episode, Bernie and Anthony review the full history of APL treatment, in preparation for the upcoming plenary presentation of the APOLLO study THIS WEEKEND at EHA 2024!

How did we get to our current standard of care in APL? How and why did the PETHEMA, GIMEMA, UK MRC, and other cooperative group regimens evolve over time into what they are today?

And importantly, is the APOLLO control arm (no arsenic!), ok? Tune in to find out!

In this episode, Anthony and Bernie are joined by Multiple Myeloma expert Dr. Manni Mohyuddin, to discuss the recent FDA approval updates of CAR-T in this disease state. We also discuss the hotly debated topic of MRD as a surrogate endpoint for accelerated approval in Myeloma.

In this episode, Anthony and Bernie review the most impactful and interesting ALL abstracts at the 2023 ASH Annual Meeting. We dive into the nelarabine abstracts, calaspargase (cal-peg), and the evolution of the treatment of Ph+ ALL!

Abstracts discussed:

• https://ash.confex.com/ash/2023/webprogram/Paper190141.html - COG AYA Outcomes (and silly nelarabine conclusions)
• https://ash.confex.com/ash/2023/webprogram/Paper177696.html - ATRIALL Nelarabine study
• https://ash.confex.com/ash/2023/webprogram/Paper179562.html - HyperCVAD + Nelarabine + PEG + venetoclax
• https://ash.confex.com/ash/2023/webprogram/Paper179192.html - ALL-TARGET Study in R/R T-ALL
• https://ash.confex.com/ash/2023/webprogram/Paper187694.html - Cal-PEG is toxic
• https://ash.confex.com/ash/2023/webprogram/Paper188064.html - Ponatinib + Blinatumomab
• https://ash.confex.com/ash/2023/webprogram/Paper187773.html - D-ALBA (Dasatinib + Blinatumomab)
• https://ash.confex.com/ash/2023/webprogram/Paper189632.html - GIMEMA (Dasatinib or Ponatinib + Blinatumomab)